http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BioDelivery Sciences (BDSI) Announces Two New Patents Expanding Protection on BELBUCA, BUNAVAIL and ONSOLIS
-
BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in FDA's Orange Book Further Extending and Strengthening Patent Protection on BELBUCA®, BUNAVAIL® and ONSOLIS®
-
BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
-
BioDelivery Sciences to Present at the 29th Annual ROTH Conference
-
BioDelivery Sciences Secures Debt Financing with CRG
-
BioDelivery Sciences Closes Transaction to Reacquire License to BELBUCA® from Endo Pharmaceuticals
-
BioDelivery Sciences Announces the Hiring of Peter Ginsberg as Vice President of Business Development
-
BioDelivery Sciences (BDSI) Says Phase 2b Trial of Clonidine Topical Gel Fails to Meet its Primary Efficacy Endpoint
-
BioDelivery Sciences Announces Clonidine Topical Gel for Painful Diabetic Neuropathy Phase 2b Trial Fails to Meet its Primary Efficacy Endpoint
-
BioDelivery Sciences (BDSI) Announces Reacquisition of BELBUCA Rights from Endo (ENDP)
-
BioDelivery Sciences Reacquires License to BELBUCA™ from Endo Pharmaceuticals
-
BioDelivery Sciences to Present at the 28th Annual Piper Jaffray Healthcare Conference
-
BioDelivery Sciences Provides Corporate Update and Reports Third Quarter 2016 Financial Results
-
BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2016 Financial Results on Wednesday, November 9
-
BioDelivery Sciences' (BDSI) BUNAVAIL Added to Texas Medicaid Formulary
-
BioDelivery Sciences Announces Preferred Formulary Status for BUNAVAIL on Texas Medicaid
-
BioDelivery Sciences Announces Additions to its Board of Directors
-
BioDelivery Sciences Cites Impressive Number of Physicians Granted Waiver to Increase Patient Limit for Opioid Dependence Treatment Following Recent HHS Rule
-
Pre-Open Stock Movers 09/23: (MIFI) (BATS) (TWTR) Higher; (ENPH) (IPCI) (APRI) Lower (more...)
-
BioDelivery Sciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference
-
BioDelivery Sciences Announces Three New Managed Care Agreements; Further Enhancing Access to BUNAVAIL
-
BioDelivery Sciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference and the 7th Annual Credit Suisse Small and Mid Cap Conference
-
BioDelivery Sciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference and the 7th Annual Credit Suisse Small and Mid Cap Conference
-
Streetinsider.com's Hot Lunchtime Reads 8/10: (TWTR) (FOMX) (BDSI) (HRTX)
-
BioDelivery Sciences Announces Randomization Target Reached in Clinical Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy
-
BioDelivery Sciences (BDSI) Gains Preferred Formulary Status for BUNAVAIL
-
BioDelivery Sciences Announces the Securing of Preferred Formulary Status for BUNAVAIL on a Significant Managed Care Plan
-
BioDelivery Sciences to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
-
BioDelivery Sciences (BDSI) Presents Data on Opioids at ASCO 2016
-
BioDelivery Sciences Announces Presentation of Data on the Impact of a State Formulary Conversion to BUNAVAIL® at the International Conference on Opioids
-
BioDelivery Sciences Announces Presentation of Data on the Impact of a State Formulary Conversion to BUNAVAIL® at the International Conference on Opioids
-
BioDelivery Sciences to Present at the Jefferies 2016 Healthcare Conference
-
BioDelivery Sciences Provides Corporate Update and Reports First Quarter 2016 Financial Results
-
BioDelivery Sciences to Host Conference Call and Webcast of First Quarter 2016 Results on Tuesday, May 10
-
BioDelivery Sciences Announces Acceptance of an Abstract to the International Conference on Opioids on the Impact of a State Formulary Conversion to BUNAVAIL
-
BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results
-
BioDelivery Sciences to Present at the Cowen and Company 36th Annual Healthcare Conference and the 28th Annual ROTH Conference
-
BioDelivery Sciences to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Results on Thursday, March 10
-
BioDelivery Sciences (BDSI) Launches BELBUCA Buccal Film
-
BioDelivery Sciences Announces the Launch of BELBUCA™ (Buprenorphine) Buccal Film by Endo Pharmaceuticals for Chronic Pain Management
-
BioDelivery Sciences to Webcast Analyst & Investor Day on February 25th
-
BioDelivery Sciences to Host Analyst and Investor Day on February 25th in New York City
-
BioDelivery Sciences (BDSI) Updates on Pipeline; Has Initiated Clonidine Topical Gel Study in Diabetic Neuropathy
-
BioDelivery Sciences Provides Pipeline Update
-
BioDelivery Sciences Announces Organizational Changes
-
BioDelivery Sciences Hires Joseph M. Lockhart as Vice President of Manufacturing and Supply Chain
-
BioDelivery Sciences to Present at the Jefferies 2015 Global Healthcare Conference
-
BioDelivery Sciences Provides Corporate Update and Reports Third Quarter 2015 Financial Results
-
BioDelivery Sciences to Host Conference Call and Webcast of Third Quarter 2015 Results on Monday, November 9
-
BioDelivery Sciences Announces FDA Approval of Change in BUNAVAIL® Product Specification Allowing for Immediate Release of Product

